Business Wire·Oct 9, 2026, 4:05 PM ET

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

Accendra Health received a notice from the NYSE on October 6, 2026, stating its Class A Common Stock is not in compliance due to an average closing price below $1.00 over 30 consecutive trading days.
The notice does not trigger immediate delisting, \& the Company intends to respond within ten business days affirming its intent to cure the deficiency.
The Company has a six-month period following receipt of the notice to regain compliance with the NYSE minimum share price requirement.
Potential remedies to cure the deficiency include a reverse stock split, which would require stockholder approval at the next annual meeting anticipated in May 2027.
Compliance can be regained at any time during the six-month cure period if the stock achieves a closing price \& a 30-day average closing price of at least $1.00 by the last trading day of a calendar month.
The Common Stock will continue to trade on the NYSE during this period, subject to compliance with other listing standards.
The notice does not affect the Company's business, operations, or SEC reporting requirements.
Forward-looking statements regarding future prospects, listing maintenance, \& stock price expectations are included with disclaimers about known risks \& uncertainties.